ProCE Banner Activity

Ruxolitinib + Azacitidine in Newly Diagnosed or R/R, Intermediate- or High-Risk Myelofibrosis

Slideset Download
Conference Coverage
Overall reduction of splenomegaly by > 50% occurred in 79% of MF patients on combination ruxolitinib plus azacitidine.

Released: December 07, 2016

Expiration: December 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen